SG10201912341SA - TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES - Google Patents
TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASESInfo
- Publication number
- SG10201912341SA SG10201912341SA SG10201912341SA SG10201912341SA SG10201912341SA SG 10201912341S A SG10201912341S A SG 10201912341SA SG 10201912341S A SG10201912341S A SG 10201912341SA SG 10201912341S A SG10201912341S A SG 10201912341SA SG 10201912341S A SG10201912341S A SG 10201912341SA
- Authority
- SG
- Singapore
- Prior art keywords
- ttr
- transthyretin
- treating
- methods
- associated diseases
- Prior art date
Links
- 108010071690 Prealbumin Proteins 0.000 title 2
- 102000009190 Transthyretin Human genes 0.000 title 2
- 201000010099 disease Diseases 0.000 title 1
- 208000037265 diseases, disorders, signs and symptoms Diseases 0.000 title 1
- 239000000203 mixture Substances 0.000 title 1
Classifications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
- C12N15/09—Recombinant DNA-technology
- C12N15/11—DNA or RNA fragments; Modified forms thereof; Non-coding nucleic acids having a biological activity
- C12N15/113—Non-coding nucleic acids modulating the expression of genes, e.g. antisense oligonucleotides; Antisense DNA or RNA; Triplex- forming oligonucleotides; Catalytic nucleic acids, e.g. ribozymes; Nucleic acids used in co-suppression or gene silencing
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K31/00—Medicinal preparations containing organic active ingredients
- A61K31/70—Carbohydrates; Sugars; Derivatives thereof
- A61K31/7088—Compounds having three or more nucleosides or nucleotides
- A61K31/713—Double-stranded nucleic acids or oligonucleotides
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K48/00—Medicinal preparations containing genetic material which is inserted into cells of the living body to treat genetic diseases; Gene therapy
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/02—Drugs for disorders of the nervous system for peripheral neuropathies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P25/00—Drugs for disorders of the nervous system
- A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P43/00—Drugs for specific purposes, not provided for in groups A61P1/00-A61P41/00
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P5/00—Drugs for disorders of the endocrine system
- A61P5/14—Drugs for disorders of the endocrine system of the thyroid hormones, e.g. T3, T4
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P7/00—Drugs for disorders of the blood or the extracellular fluid
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P9/00—Drugs for disorders of the cardiovascular system
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q1/00—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions
- C12Q1/68—Measuring or testing processes involving enzymes, nucleic acids or microorganisms; Compositions therefor; Processes of preparing such compositions involving nucleic acids
- C12Q1/6876—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes
- C12Q1/6883—Nucleic acid products used in the analysis of nucleic acids, e.g. primers or probes for diseases caused by alterations of genetic material
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N33/00—Investigating or analysing materials by specific methods not covered by groups G01N1/00 - G01N31/00
- G01N33/48—Biological material, e.g. blood, urine; Haemocytometers
- G01N33/50—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing
- G01N33/68—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids
- G01N33/6893—Chemical analysis of biological material, e.g. blood, urine; Testing involving biospecific ligand binding methods; Immunological testing involving proteins, peptides or amino acids related to diseases not provided for elsewhere
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/10—Type of nucleic acid
- C12N2310/14—Type of nucleic acid interfering N.A.
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/31—Chemical structure of the backbone
- C12N2310/315—Phosphorothioates
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/321—2'-O-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/32—Chemical structure of the sugar
- C12N2310/322—2'-R Modification
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/34—Spatial arrangement of the modifications
- C12N2310/344—Position-specific modifications, e.g. on every purine, at the 3'-end
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/351—Conjugate
- C12N2310/3515—Lipophilic moiety, e.g. cholesterol
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2310/00—Structure or type of the nucleic acid
- C12N2310/30—Chemical structure
- C12N2310/35—Nature of the modification
- C12N2310/353—Nature of the modification linked to the nucleic acid via an atom other than carbon
- C12N2310/3533—Halogen
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
- C12N2320/00—Applications; Uses
- C12N2320/30—Special therapeutic applications
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/158—Expression markers
-
- C—CHEMISTRY; METALLURGY
- C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
- C12Q—MEASURING OR TESTING PROCESSES INVOLVING ENZYMES, NUCLEIC ACIDS OR MICROORGANISMS; COMPOSITIONS OR TEST PAPERS THEREFOR; PROCESSES OF PREPARING SUCH COMPOSITIONS; CONDITION-RESPONSIVE CONTROL IN MICROBIOLOGICAL OR ENZYMOLOGICAL PROCESSES
- C12Q2600/00—Oligonucleotides characterized by their use
- C12Q2600/178—Oligonucleotides characterized by their use miRNA, siRNA or ncRNA
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2333/00—Assays involving biological materials from specific organisms or of a specific nature
- G01N2333/435—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans
- G01N2333/46—Assays involving biological materials from specific organisms or of a specific nature from animals; from humans from vertebrates
- G01N2333/47—Assays involving proteins of known structure or function as defined in the subgroups
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/22—Haematology
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/28—Neurological disorders
- G01N2800/2814—Dementia; Cognitive disorders
-
- G—PHYSICS
- G01—MEASURING; TESTING
- G01N—INVESTIGATING OR ANALYSING MATERIALS BY DETERMINING THEIR CHEMICAL OR PHYSICAL PROPERTIES
- G01N2800/00—Detection or diagnosis of diseases
- G01N2800/32—Cardiovascular disorders
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Engineering & Computer Science (AREA)
- Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Organic Chemistry (AREA)
- General Health & Medical Sciences (AREA)
- Biomedical Technology (AREA)
- Genetics & Genomics (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Animal Behavior & Ethology (AREA)
- Public Health (AREA)
- Veterinary Medicine (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- General Chemical & Material Sciences (AREA)
- Chemical Kinetics & Catalysis (AREA)
- Molecular Biology (AREA)
- Biotechnology (AREA)
- Zoology (AREA)
- Wood Science & Technology (AREA)
- Neurology (AREA)
- Neurosurgery (AREA)
- General Engineering & Computer Science (AREA)
- Biochemistry (AREA)
- Microbiology (AREA)
- Physics & Mathematics (AREA)
- Biophysics (AREA)
- Plant Pathology (AREA)
- Diabetes (AREA)
- Hematology (AREA)
- Epidemiology (AREA)
- Proteomics, Peptides & Aminoacids (AREA)
- Analytical Chemistry (AREA)
- Psychiatry (AREA)
- Hospice & Palliative Care (AREA)
- Immunology (AREA)
- Urology & Nephrology (AREA)
- Endocrinology (AREA)
- Heart & Thoracic Surgery (AREA)
Applications Claiming Priority (2)
Application Number | Priority Date | Filing Date | Title |
---|---|---|---|
US201562199563P | 2015-07-31 | 2015-07-31 | |
US201662287518P | 2016-01-27 | 2016-01-27 |
Publications (1)
Publication Number | Publication Date |
---|---|
SG10201912341SA true SG10201912341SA (en) | 2020-02-27 |
Family
ID=56682264
Family Applications (1)
Application Number | Title | Priority Date | Filing Date |
---|---|---|---|
SG10201912341SA SG10201912341SA (en) | 2015-07-31 | 2016-07-28 | TRANSTHYRETIN (TTR) iRNA COMPOSITIONS AND METHODS OF USE THEREOF FOR TREATING OR PREVENTING TTR-ASSOCIATED DISEASES |
Country Status (33)
Country | Link |
---|---|
US (4) | US10208307B2 (ru) |
EP (1) | EP3329002B1 (ru) |
JP (3) | JP6896703B2 (ru) |
KR (2) | KR20240074895A (ru) |
CN (2) | CN116064515A (ru) |
BR (1) | BR112018000542B1 (ru) |
CA (1) | CA2994285A1 (ru) |
CL (1) | CL2018000198A1 (ru) |
CY (1) | CY1124545T1 (ru) |
DK (1) | DK3329002T3 (ru) |
EA (1) | EA201890394A1 (ru) |
ES (1) | ES2842300T3 (ru) |
FI (1) | FIC20230006I1 (ru) |
FR (1) | FR23C1008I2 (ru) |
HK (2) | HK1256494A1 (ru) |
HR (1) | HRP20202082T1 (ru) |
HU (2) | HUE051998T2 (ru) |
IL (2) | IL296476B1 (ru) |
LT (2) | LT3329002T (ru) |
MA (1) | MA43335B1 (ru) |
MX (2) | MX2018000981A (ru) |
MY (1) | MY195720A (ru) |
NL (1) | NL301216I2 (ru) |
NO (1) | NO2023007I1 (ru) |
PL (1) | PL3329002T3 (ru) |
PT (1) | PT3329002T (ru) |
RS (1) | RS61297B1 (ru) |
SG (1) | SG10201912341SA (ru) |
SI (1) | SI3329002T1 (ru) |
TW (3) | TWI807302B (ru) |
UA (1) | UA126276C2 (ru) |
WO (1) | WO2017023660A1 (ru) |
ZA (2) | ZA201800571B (ru) |
Families Citing this family (23)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
CN102282155B (zh) | 2008-12-02 | 2017-06-09 | 日本波涛生命科学公司 | 磷原子修饰的核酸的合成方法 |
IN2012DN00720A (ru) | 2009-07-06 | 2015-06-19 | Ontorii Inc | |
EP2563920B1 (en) | 2010-04-29 | 2017-03-15 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
DK2620428T3 (da) | 2010-09-24 | 2019-07-01 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
JP6128529B2 (ja) | 2011-07-19 | 2017-05-17 | ウェイブ ライフ サイエンシズ リミテッドWave Life Sciences Ltd. | 官能化核酸の合成のための方法 |
JP2015502931A (ja) | 2011-11-18 | 2015-01-29 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 修飾RNAi剤 |
IN2014CN03463A (ru) * | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
DK2872485T3 (da) | 2012-07-13 | 2021-03-08 | Wave Life Sciences Ltd | Asymmetrisk hjælpegruppe |
WO2014012081A2 (en) | 2012-07-13 | 2014-01-16 | Ontorii, Inc. | Chiral control |
JPWO2015108048A1 (ja) | 2014-01-15 | 2017-03-23 | 株式会社新日本科学 | 抗腫瘍作用を有するキラル核酸アジュバンド及び抗腫瘍剤 |
US10144933B2 (en) | 2014-01-15 | 2018-12-04 | Shin Nippon Biomedical Laboratories, Ltd. | Chiral nucleic acid adjuvant having immunity induction activity, and immunity induction activator |
KR20220106232A (ko) | 2014-01-16 | 2022-07-28 | 웨이브 라이프 사이언시스 리미티드 | 키랄 디자인 |
KR20240074895A (ko) * | 2015-07-31 | 2024-05-28 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물 및 TTR-관련 질병을 치료하거나, 예방하기 위한 그의 사용 방법 |
JOP20210043A1 (ar) * | 2015-10-01 | 2017-06-16 | Arrowhead Pharmaceuticals Inc | تراكيب وأساليب لتثبيط تعبير جيني للـ lpa |
TW202317151A (zh) * | 2016-12-16 | 2023-05-01 | 美商阿尼拉製藥公司 | 使用甲狀腺素運載蛋白(TTR)iRNA組成物於治療或預防TTR相關疾病之方法 |
MA50267A (fr) | 2017-09-19 | 2020-07-29 | Alnylam Pharmaceuticals Inc | Compositions et méthodes de traitement de l'amylose médiée par la transthyrétine (ttr) |
JP2021504415A (ja) * | 2017-12-01 | 2021-02-15 | スーチョウ リボ ライフ サイエンス カンパニー、リミテッドSuzhou Ribo Life Science Co., Ltd. | 二本鎖オリゴヌクレオチド、二本鎖オリゴヌクレオチドを含む組成物および複合体ならびに調製方法と使用 |
TW202028465A (zh) | 2018-09-28 | 2020-08-01 | 美商阿尼拉製藥公司 | 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法 |
WO2021041884A1 (en) | 2019-08-30 | 2021-03-04 | Alnylam Pharmaceuticals, Inc. | Neurofilament light chain (nfl) as a biomarker for transthyretin amyloidosis polyneuropathy |
JP2023516748A (ja) | 2020-03-06 | 2023-04-20 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | トランスサイレチン(ttr)の発現を阻害するための組成物および方法 |
JP2023548005A (ja) * | 2020-10-28 | 2023-11-15 | ノヴォ ノルディスク アー/エス | 抗トランスサイレチン抗体およびその使用方法 |
AR126070A1 (es) | 2021-06-08 | 2023-09-06 | Alnylam Pharmaceuticals Inc | Composiciones y métodos para tratar o prevenir la enfermedad de stargardt y/o trastornos asociados con la proteína transportadora de retinol 4 (rbp4) |
EP4381067A1 (en) | 2021-08-03 | 2024-06-12 | Alnylam Pharmaceuticals, Inc. | Transthyretin (ttr) irna compositions and methods of use thereof |
Family Cites Families (68)
Publication number | Priority date | Publication date | Assignee | Title |
---|---|---|---|---|
US20030027216A1 (en) | 2001-07-02 | 2003-02-06 | Kiernan Urban A. | Analysis of proteins from biological fluids using mass spectrometric immunoassay |
EP1261620A2 (en) | 2000-02-07 | 2002-12-04 | Roche Diagnostics Corporation | Cationic amphiphiles for use in nucleic acid transfection |
US20030072794A1 (en) | 2000-06-09 | 2003-04-17 | Teni Boulikas | Encapsulation of plasmid DNA (lipogenes™) and therapeutic agents with nuclear localization signal/fusogenic peptide conjugates into targeted liposome complexes |
ES2728168T3 (es) | 2000-12-01 | 2019-10-22 | Max Planck Gesellschaft | Moléculas pequeñas de ARN que median en la interferencia de ARN |
US20020160394A1 (en) | 2001-01-24 | 2002-10-31 | Bayer Corporation | Regulation of transthyretin to treat obesity |
EP1386004A4 (en) | 2001-04-05 | 2005-02-16 | Ribozyme Pharm Inc | MODULATION OF GENE EXPRESSION ASSOCIATED WITH INFLAMMATORY PROLIFERATION AND GROWTH OF NEURITIES BY METHODS INVOLVING NUCLEIC ACID |
US20030170891A1 (en) | 2001-06-06 | 2003-09-11 | Mcswiggen James A. | RNA interference mediated inhibition of epidermal growth factor receptor gene expression using short interfering nucleic acid (siNA) |
US7514099B2 (en) | 2005-02-14 | 2009-04-07 | Sirna Therapeutics, Inc. | Lipid nanoparticle based compositions and methods for the delivery of biologically active molecules |
US20030124616A1 (en) | 2001-06-21 | 2003-07-03 | Jacobsen Donald W. | Homocysteinylated transthyretin |
US20030191056A1 (en) | 2002-04-04 | 2003-10-09 | Kenneth Walker | Use of transthyretin peptide/protein fusions to increase the serum half-life of pharmacologically active peptides/proteins |
BRPI0313202A8 (pt) | 2002-08-05 | 2016-08-16 | Atugen Ag | Formas adicionais para interferir com as moléculas de rna |
US7956176B2 (en) | 2002-09-05 | 2011-06-07 | Sirna Therapeutics, Inc. | RNA interference mediated inhibition of gene expression using chemically modified short interfering nucleic acid (siNA) |
EP1556684A4 (en) | 2002-11-01 | 2008-01-23 | Univ Colorado Regents | QUANTITATIVE ANALYSIS OF PROTEIN ISOFORMS USING FLIGHT TIME MASS SPECTROMETRY BY MATRIX ASSISTED LASER DESORPTION / IONIZATION |
EP2284266B1 (en) | 2002-11-14 | 2013-11-06 | Thermo Fisher Scientific Biosciences Inc. | siRNA targeting tp53 |
US9228186B2 (en) | 2002-11-14 | 2016-01-05 | Thermo Fisher Scientific Inc. | Methods and compositions for selecting siRNA of improved functionality |
US7250496B2 (en) | 2002-11-14 | 2007-07-31 | Rosetta Genomics Ltd. | Bioinformatically detectable group of novel regulatory genes and uses thereof |
WO2004090108A2 (en) | 2003-04-03 | 2004-10-21 | Alnylam Pharmaceuticals | Irna conjugates |
DK2216407T3 (en) | 2003-03-07 | 2016-03-29 | Alnylam Pharmaceuticals Inc | therapeutic compositions |
EP2567693B1 (en) | 2003-07-16 | 2015-10-21 | Protiva Biotherapeutics Inc. | Lipid encapsulated interfering RNA |
US20050244869A1 (en) | 2004-04-05 | 2005-11-03 | Brown-Driver Vickie L | Modulation of transthyretin expression |
EP1766071A4 (en) | 2004-06-03 | 2009-11-11 | Isis Pharmaceuticals Inc | DOUBLE-STRONG COMPOSITIONS WITH DIFFERENTLY MODIFIED STRANDS FOR USE IN GENE MODULATION |
US7799565B2 (en) | 2004-06-07 | 2010-09-21 | Protiva Biotherapeutics, Inc. | Lipid encapsulated interfering RNA |
WO2005120152A2 (en) | 2004-06-07 | 2005-12-22 | Protiva Biotherapeutics, Inc. | Cationic lipids and methods of use |
US7838561B2 (en) | 2004-06-14 | 2010-11-23 | Wisconsin Alumni Research Foundation | Method for preventing or treating cardiac hypertrophy |
MX2007006245A (es) | 2004-12-08 | 2007-07-25 | Sirion Therapeutics Inc | Metodos, analisis y composiciones para tratar enfermedades relacionadas con retinol. |
ES2381201T3 (es) | 2005-03-31 | 2012-05-24 | Calando Pharmaceuticals, Inc. | Inhibidores de la subunidad 2 de la ribonucleótido-reductasa y utilizaciones de los mismos |
US7915230B2 (en) | 2005-05-17 | 2011-03-29 | Molecular Transfer, Inc. | Reagents for transfection of eukaryotic cells |
JP5639338B2 (ja) | 2005-07-27 | 2014-12-10 | プロチバ バイオセラピューティクス インコーポレイティッド | リポソームの製造システムおよび製造方法 |
JP5336853B2 (ja) | 2005-11-02 | 2013-11-06 | プロチバ バイオセラピューティクス インコーポレイティッド | 修飾siRNA分子およびその使用法 |
KR20150038522A (ko) | 2006-03-31 | 2015-04-08 | 알닐람 파마슈티칼스 인코포레이티드 | Eg5 유전자의 발현을 억제하는 이본쇄 리보핵산 |
US8598333B2 (en) | 2006-05-26 | 2013-12-03 | Alnylam Pharmaceuticals, Inc. | SiRNA silencing of genes expressed in cancer |
EP2695608B1 (en) | 2006-10-03 | 2016-11-23 | Arbutus Biopharma Corporation | Lipid containing formulations |
GB0704764D0 (en) | 2007-03-12 | 2007-04-18 | Electrophoretics Ltd | Isobarically labelled reagents and methods of their use |
US20110046206A1 (en) | 2007-06-22 | 2011-02-24 | Isis Pharmaceuticals, Inc. | Double strand compositions comprising differentially modified strands for use in gene modulation |
US8106022B2 (en) | 2007-12-04 | 2012-01-31 | Alnylam Pharmaceuticals, Inc. | Carbohydrate conjugates as delivery agents for oligonucleotides |
WO2009082817A1 (en) | 2007-12-27 | 2009-07-09 | Protiva Biotherapeutics, Inc. | Silencing of polo-like kinase expression using interfering rna |
EP2224912B1 (en) | 2008-01-02 | 2016-05-11 | TEKMIRA Pharmaceuticals Corporation | Improved compositions and methods for the delivery of nucleic acids |
CA2713379A1 (en) | 2008-01-31 | 2009-11-05 | Alnylam Pharmaceuticals, Inc. | Optimized methods for delivery of dsrna targeting the pcsk9 gene |
WO2009100390A2 (en) | 2008-02-08 | 2009-08-13 | Mayo Foundation For Medical Education And Research | Classifying amyloidosis |
JP5475753B2 (ja) | 2008-04-15 | 2014-04-16 | プロチバ バイオセラピューティクス インコーポレイティッド | 核酸送達用の脂質製剤 |
TWI455944B (zh) | 2008-07-01 | 2014-10-11 | Daiichi Sankyo Co Ltd | 雙股多核苷酸 |
US20110237646A1 (en) | 2008-08-07 | 2011-09-29 | Isis Pharmaceuticals, Inc. | Modulation of transthyretin expression for the treatment of cns related disorders |
US9139554B2 (en) | 2008-10-09 | 2015-09-22 | Tekmira Pharmaceuticals Corporation | Amino lipids and methods for the delivery of nucleic acids |
MX360460B (es) | 2008-10-20 | 2018-11-05 | Alnylam Pharmaceuticals Inc | Composiciones y metodos para inhibir la expresion de transtiretina. |
WO2010053572A2 (en) | 2008-11-07 | 2010-05-14 | Massachusetts Institute Of Technology | Aminoalcohol lipidoids and uses thereof |
NO2355851T3 (ru) | 2008-11-10 | 2018-09-01 | ||
US9493774B2 (en) | 2009-01-05 | 2016-11-15 | Rxi Pharmaceuticals Corporation | Inhibition of PCSK9 through RNAi |
AU2010208035B2 (en) | 2009-01-29 | 2016-06-23 | Arbutus Biopharma Corporation | Improved lipid formulation for the delivery of nucleic acids |
SG10201911942UA (en) | 2009-05-05 | 2020-02-27 | Muthiah Manoharan | Lipid compositions |
CN102625696B (zh) | 2009-06-10 | 2015-06-03 | 阿尔尼拉姆医药品有限公司 | 改进的脂质制剂 |
US9051567B2 (en) | 2009-06-15 | 2015-06-09 | Tekmira Pharmaceuticals Corporation | Methods for increasing efficacy of lipid formulated siRNA |
MX2011013421A (es) | 2009-06-15 | 2012-03-16 | Alnylam Pharmaceuticals Inc | Arnds formulado con lipido de direccionamiento del gen pcsk9. |
US9101643B2 (en) | 2009-11-03 | 2015-08-11 | Alnylam Pharmaceuticals, Inc. | Lipid formulated compositions and methods for inhibiting expression of transthyretin (TTR) |
WO2011123468A1 (en) | 2010-03-29 | 2011-10-06 | Alnylam Pharmaceuticals, Inc. | Sirna therapy for transthyretin (ttr) related ocular amyloidosis |
EP2563920B1 (en) | 2010-04-29 | 2017-03-15 | Ionis Pharmaceuticals, Inc. | Modulation of transthyretin expression |
EP2616543A1 (en) | 2010-09-15 | 2013-07-24 | Alnylam Pharmaceuticals, Inc. | MODIFIED iRNA AGENTS |
WO2012058210A1 (en) | 2010-10-29 | 2012-05-03 | Merck Sharp & Dohme Corp. | RNA INTERFERENCE MEDIATED INHIBITION OF GENE EXPRESSION USING SHORT INTERFERING NUCLEIC ACIDS (siNA) |
JP2014526882A (ja) | 2011-06-21 | 2014-10-09 | アルナイラム ファーマシューティカルズ, インコーポレイテッド | 対象中の治療剤の活性を判定するアッセイおよび方法 |
JP2015502931A (ja) | 2011-11-18 | 2015-01-29 | アルナイラム ファーマシューティカルズ, インコーポレイテッドAlnylam Pharmaceuticals, Inc. | 修飾RNAi剤 |
IN2014CN03463A (ru) * | 2011-11-18 | 2015-10-09 | Alnylam Pharmaceuticals Inc | |
WO2014022739A2 (en) | 2012-08-03 | 2014-02-06 | Alnylam Pharmaceuticals, Inc. | Modified rnai agents |
TW201610151A (zh) * | 2013-09-23 | 2016-03-16 | 阿尼拉製藥公司 | 治療或預防與甲狀腺素運載蛋白相關疾病之方法 |
CA2932904A1 (en) | 2013-12-06 | 2015-06-11 | Dicerna Pharmaceuticals, Inc. | Methods and compositions for the specific inhibition of transthyretin (ttr) by double-stranded rna |
WO2015089368A2 (en) * | 2013-12-12 | 2015-06-18 | Alnylam Pharmaceuticals, Inc. | Complement component irna compositions and methods of use thereof |
SG10201913791QA (en) | 2014-08-20 | 2020-03-30 | Alnylam Pharmaceuticals Inc | Modified double-stranded rna agents |
KR20220087571A (ko) | 2014-08-29 | 2022-06-24 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스타이레틴(ttr) 매개 아밀로이드증의 치료 방법 |
KR20240074895A (ko) | 2015-07-31 | 2024-05-28 | 알닐람 파마슈티칼스 인코포레이티드 | 트랜스티레틴(TTR) iRNA 조성물 및 TTR-관련 질병을 치료하거나, 예방하기 위한 그의 사용 방법 |
TW202028465A (zh) | 2018-09-28 | 2020-08-01 | 美商阿尼拉製藥公司 | 甲狀腺素運載蛋白(TTR)iRNA組成物及其治療或預防TTR相關眼部疾病之使用方法 |
-
2016
- 2016-07-28 KR KR1020247015927A patent/KR20240074895A/ko active Application Filing
- 2016-07-28 MA MA43335A patent/MA43335B1/fr unknown
- 2016-07-28 EA EA201890394A patent/EA201890394A1/ru unknown
- 2016-07-28 SI SI201631039T patent/SI3329002T1/sl unknown
- 2016-07-28 RS RS20210015A patent/RS61297B1/sr unknown
- 2016-07-28 HU HUE16750567A patent/HUE051998T2/hu unknown
- 2016-07-28 SG SG10201912341SA patent/SG10201912341SA/en unknown
- 2016-07-28 JP JP2018504819A patent/JP6896703B2/ja active Active
- 2016-07-28 MY MYPI2018700351A patent/MY195720A/en unknown
- 2016-07-28 CN CN202210881662.9A patent/CN116064515A/zh active Pending
- 2016-07-28 EP EP16750567.6A patent/EP3329002B1/en active Active
- 2016-07-28 IL IL296476A patent/IL296476B1/en unknown
- 2016-07-28 WO PCT/US2016/044359 patent/WO2017023660A1/en active Application Filing
- 2016-07-28 MX MX2018000981A patent/MX2018000981A/es unknown
- 2016-07-28 CA CA2994285A patent/CA2994285A1/en active Pending
- 2016-07-28 CN CN201680057293.4A patent/CN108138182B/zh active Active
- 2016-07-28 PL PL16750567T patent/PL3329002T3/pl unknown
- 2016-07-28 DK DK16750567.6T patent/DK3329002T3/da active
- 2016-07-28 BR BR112018000542-8A patent/BR112018000542B1/pt active IP Right Grant
- 2016-07-28 ES ES16750567T patent/ES2842300T3/es active Active
- 2016-07-28 KR KR1020187005958A patent/KR102667020B1/ko active IP Right Grant
- 2016-07-28 PT PT167505676T patent/PT3329002T/pt unknown
- 2016-07-28 US US15/221,651 patent/US10208307B2/en active Active
- 2016-07-28 UA UAA201802022A patent/UA126276C2/uk unknown
- 2016-07-28 LT LTEP16750567.6T patent/LT3329002T/lt unknown
- 2016-07-29 TW TW110113415A patent/TWI807302B/zh active
- 2016-07-29 TW TW112123223A patent/TW202344688A/zh unknown
- 2016-07-29 TW TW105124065A patent/TWI727963B/zh active
-
2017
- 2017-12-27 IL IL256614A patent/IL256614B2/en unknown
-
2018
- 2018-01-23 MX MX2023012080A patent/MX2023012080A/es unknown
- 2018-01-24 CL CL2018000198A patent/CL2018000198A1/es unknown
- 2018-01-26 ZA ZA2018/00571A patent/ZA201800571B/en unknown
- 2018-12-05 HK HK18115560.8A patent/HK1256494A1/zh unknown
- 2018-12-06 HK HK18115667.0A patent/HK1256683A1/zh unknown
- 2018-12-18 US US16/223,362 patent/US10683501B2/en active Active
-
2019
- 2019-04-17 ZA ZA2019/02447A patent/ZA201902447B/en unknown
-
2020
- 2020-05-01 US US16/864,226 patent/US11286486B2/en active Active
- 2020-12-31 HR HRP20202082TT patent/HRP20202082T1/hr unknown
-
2021
- 2021-01-07 CY CY20211100010T patent/CY1124545T1/el unknown
- 2021-06-09 JP JP2021096344A patent/JP7417559B2/ja active Active
-
2022
- 2022-01-26 US US17/584,463 patent/US20230022185A1/en active Pending
-
2023
- 2023-02-06 NL NL301216C patent/NL301216I2/nl unknown
- 2023-02-06 FI FIC20230006C patent/FIC20230006I1/fi unknown
- 2023-02-07 NO NO2023007C patent/NO2023007I1/no unknown
- 2023-02-08 LT LTPA2023505C patent/LTPA2023505I1/lt unknown
- 2023-02-08 FR FR23C1008C patent/FR23C1008I2/fr active Active
- 2023-02-09 HU HUS2300007C patent/HUS2300007I1/hu unknown
- 2023-11-24 JP JP2023199064A patent/JP2024028749A/ja active Pending
Also Published As
Similar Documents
Publication | Publication Date | Title |
---|---|---|
HUS2300007I1 (hu) | Transztiretin (TTR) iRNS készítmények és eljárások azok alkalmazása TTR-asszociált betegségek kezelésére vagy megelõzésére | |
IL278001B (en) | Preparations and methods for the treatment of amyotrophic lateral sclerosis | |
HK1258588A1 (zh) | 用於治療眼科疾病的化合物和製劑 | |
SG10201913552UA (en) | Methods for treating or preventing ttr-associated diseases using transthyretin (ttr) irna compositions | |
GB201706751D0 (en) | Compositions and methods for treating inflamatory diseases | |
DK3119797T3 (da) | Raav-baserede sammensætninger og fremgangsmåder til behandling af amyotrofisk lateralsklerose | |
EP3390634A4 (en) | COMPOSITIONS AND METHODS FOR THE TREATMENT OF EYE DISEASES | |
IL246791A0 (en) | Compositions and methods for treating eye diseases | |
IL253118A0 (en) | Methods for treating inflammatory diseases | |
HK1252037A1 (zh) | 治療炎性疾病的方法 | |
IL249098A0 (en) | Methods and preparations for the treatment of allergy and inflammatory diseases | |
DK3142664T3 (da) | Sammensætninger og fremgangsmåder til behandling og diagnosticering af øjensygdomme | |
DK3110446T3 (da) | Fremgangsmåder og sammensætninger til behandling af Siglec-8-associerede sygdomme | |
EP3131556A4 (en) | Methods and compositions for treatment of copd diseases | |
HK1258994A1 (zh) | 用於疾病治療的方法 | |
DK3122743T3 (da) | Sammensætninger og fremgangsmåder til behandling af neurodegenerative sygdomme | |
IL259710A (en) | Preparations and methods for the treatment of Davidson's disease (microvillus inclusion disease) and related diseases | |
EP3129361A4 (en) | Treatment of neurodegenerative diseases with asparagine endopeptidase (aep) inhibitors and compositions related thereto | |
HK1249044A1 (zh) | 用於治療或預防神經退行性疾病的槍刀藥素氧化物、其衍生物、相關化合物和激動劑 | |
HK1243937A1 (zh) | 治療疾病的方法 | |
HK1244782A1 (zh) | 用於治療疾病和病癥的組合物和方法 | |
ZA201805989B (en) | Compositions and methods of treatment of chronic infectious diseases | |
SG11201705889VA (en) | Prevention or Treatment of Uratic or Gouty Diseases |